Park, Ji Hye
(Division of Pharmaceutical Services, Asan Medical Center)
Lee, Byung Koo (College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University) Kim, Jae Youn (Division of Pharmaceutical Services, Asan Medical Center) Gwak, Hye Sun (College of Pharmacy & Division of Life and Pharmaceutical Sciences, Ewha Womans University) |
1 | Schellenberg ES, Dryden DM, Vandermeer B, Ha C, Korownyk C. Lifestyle Interventions for Patients With and at Risk for Type 2 DiabetesA Systematic Review and Meta-analysis.Ann Intern Med 2013;159(8):543-51. DOI |
2 | Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344(18):1343-50. DOI ScienceOn |
3 | Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359(15):1577-89. DOI ScienceOn |
4 | Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53. DOI ScienceOn |
5 | Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010;375(9712):408-18. DOI ScienceOn |
6 | American Diabetes Association. American Diabetes Association (ADA) guidelines: clinical practice recommendations. Diabetes Care 2006;29(Suppl. 1):S1-S85. DOI ScienceOn |
7 | Oh JY. Treatment guideline for diabetes. Korean J Intern Med. 2008;75(3):249-56. |
8 | Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35(6):1364-79. DOI ScienceOn |
9 | Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D.Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;20(3):CD002966. |
10 | Miller, Shannon A., and Erin L. St Onge. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 2006;40(7-8):1336-43. DOI |
11 | Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24(3):460-7. DOI ScienceOn |
12 | Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11(1):44-7. DOI ScienceOn |
13 | Vermeire E, Wens J, Van Royen P, Biot Y, Hearnshaw H, Lindenmeyer A. Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;18(2):CD003638. |
14 | Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318. DOI |
15 | Bramlage P, Ketelhut R, Fronk EM, et al. Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. Clin Drug Investig 2014;34(6):403-11. DOI |
16 | Gu N, Kim BH, Rhim H, et al. Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride/metformin 2/500-mg tablets versus separate tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy Korean volunteers. ClinTher 2010;32(7):1408-18. |
17 | American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care 2014;37(suppl 1):S14-80. DOI ScienceOn |
18 | Migoya EM, Miller JL, Gutierrez M, et al. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects. Clin Drug Investig 2010;30(12):855-66. DOI |
19 | He YL, Paladini S, Sabia H, et al. Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects. Int J ClinPharmacolTher 2008;46(5):259-67. |
20 | Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004;27(9): 2149-53. DOI ScienceOn |
![]() |